Author(s):
Shreyash A Manapure, Prashant V Aj, mire, Hrulesh R Salpe, Shivam Ratkal, Atharva P Malkhade, Pravin N Khatale
Email(s):
shreyashmanapure6@gmail.com , hruleshsalpe200gmail.com
DOI:
10.52711/2231-5691.2024.00006 
Address:
Shreyash A Manapure*, Prashant V Aj
mire, Hrulesh R Salpe, Shivam Ratkal, Atharva P Malkhade, Pravin N Khatale
Department of Pharmacology, Dr. Rajendra Gode Institute of Pharmacy, Amravati – 444602.
*Corresponding Author
Published In:
Volume - 14,
Issue - 1,
Year - 2024
ABSTRACT:
ABSTRACT:
Adverse drug reactions (ADRs) are one of the major problems associated with medication. Efficiency and success of any pharmacovigilance program relies heavily on the participation of all health professionals. Spontaneous ADR reporting is the cornerstone of Pharmacovigilance. Pharmacists can promote medication safety through spontaneous reporting of ADRs. However, underreporting is a huge problem due to lack of reporting culture amongst healthcare professionals, Different educational interventions and different factors (socio-demographic & professional) have been implicated to influence reporting process. The present survey was undertaken to evaluate knowledge, attitude and practices regarding ADR reporting and pharmacovigilance among the community pharmacists (20) in Amravati District; and to identify the main factors and barriers that influence ADRs reporting. It is a questionnaire based survey including 25 questions related to Pharmacovigilance, ADRs and their reporting. The responses from the community pharmacists were recorded and evaluated. From the survey it was found that, most of the pharmacists have more awareness and information about pharmacovigilance and ADR reporting compared with elderly pharmacists (age 50-60 years). Some pharmacist were unaware and lack of basic information regarding the reporting of an ADR, while some of them were found to be aware and knew the process of reporting an ADRs. Improving ADR reporting by pharmacists is essential for enhancing pharmacovigilance and ensuring patient safety. By increasing awareness and knowledge about ADRs and ADR reporting, and providing support and incentives for reporting, pharmacists can play a vital role in detecting and preventing ADRs, ultimately leading to better patient outcomes and drug safety.
Cite this article:
Shreyash A Manapure, Prashant V Aj;mire, Hrulesh R Salpe, Shivam Ratkal, Atharva P Malkhade, Pravin N Khatale. Questionnaire Based Awareness Study for Adverse Drug Reaction Reporting by the Community Pharmacist in Amravati District. Asian Journal of Pharmaceutical Research. 2024; 14(1):39-4. doi: 10.52711/2231-5691.2024.00006
Cite(Electronic):
Shreyash A Manapure, Prashant V Aj;mire, Hrulesh R Salpe, Shivam Ratkal, Atharva P Malkhade, Pravin N Khatale. Questionnaire Based Awareness Study for Adverse Drug Reaction Reporting by the Community Pharmacist in Amravati District. Asian Journal of Pharmaceutical Research. 2024; 14(1):39-4. doi: 10.52711/2231-5691.2024.00006 Available on: https://asianjpr.com/AbstractView.aspx?PID=2024-14-1-6
REFERENCES:
1. Lee A, Thomas SHL. Adverse drug reactions. In: Walker R and Edward C. Clinical Pharmacy and Therapeutics, 3rd edition. US; Churchill Livingstone. 2003: 33-46.
2. The importance of pharmacovigilance. World Health Organization, Geneva; 2002; 146- 57.
3. Aziz Z, Siang TC, Badarudin NS. Reporting of adverse drug reactions: predictors of under-reporting in Malaysia. Pharmacoepidemiol Drug Saf, 2007; 16: 223-8.
4. Olsson S. The need for pharmacovigilance. In: Gupta SK. Pharmacology and Therapeutics in the New Millennium. New Delhi; Narosa Publishing House. 2001: 502.
5. Area of works pharmacovigilance. World Health Organization. 2013 Availabel at: www.who.int/medicines/areas/quality_safety/safety_efficacy/pharmvigi.
6. Wallace SM, Suveges LG, Gesy KF. Adverse Drug Reaction Reporting Part I: A Survey of Pharmacists and Physicians in Saskatchewan. Drug Information Journal. 1995; 29(2): 571-579. doi:10.1177/009286159502900232.
7. Edwards, I. Ralph, and Jeffrey K. Aronson. Adverse drug reactions: definitions, diagnosis, and management. The Lancet. 2000; 356.9237 : 1255-1259.
8. Mulchandani, Rubina and Kakkar, Ashish Kumar. Reporting of Adverse Drug Reactions in India: A Review of the Current Scenario, Obstacles and Possible Solutions. 2019: 33 – 44.
9. Aldryhim, A. Y., Alomair, A., Alqhtani, M., Adam, M., Alshammari, T. M., Pont, L. G., Alhawassi, T. M. (2019). Factors that facilitate reporting of adverse drug reactions by pharmacists in Saudi Arabia. Expert Opinion on Drug Safety. doi:10.1080/14740338.2019.1632287
10. Hadi, M. A., Neoh, C. F., Zin, R. M., Elrggal, M., and Cheema, E. Pharmacovigilance: pharmacists’ perspective on spontaneous adverse drug reaction reporting. Integrated Pharmacy Research and Practice. 2017; 6: 91–98. doi:10.2147/iprp.s105881
11. Lemay, J., Alsaleh, F. M., Al-Buresli, L., Al-Mutairi, M., Abahussain, E. A., & Bayoud, T. Reporting of Adverse Drug Reactions in Primary Care Settings in Kuwait: A Comparative Study of Physicians and Pharmacists. Medical Principles and Practice. 2018; 27(1): 30–38. doi:10.1159/000487236
12. Wester K , Jonsson AK , Spigset O , Druid H , Hägg S . Incidence of fatal adverse drug reactions: a population-based study. Br J Clin Pharmacol. 2008; 65: 573 – 9 .
13. Olivier P, Montastruc JL. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France. Pharmacoepidemiol Drug Saf. 2006; 15: 808–812
14. Rawlins MD, Thompson JW. Mechanisms of adverse drug reactions. In Textbook of adverse drug reactions, Davies DM (ed.). Oxford University Press: Oxford. 1985; 12–38.
15. Anatomical therapeutic chemical (ATC) classification index. WHO Collaborating Center for Drug Statistics Methodology: Geneva. 1992.
16. Clarke A, Deeks JJ, Shakir SAW. An assessment of the publicly disseminated evidence of safety used in decisions to withdraw medicinal products from the UK and US markets. Drug Saf. 2006; 29: 175–181.
17. Arnaiz JA, Carne X, Riba N, et al. The use of evidence in pharmacovigilance. Case reports as the reference source for drug withdrawals. Eur J Clin Pharmacol. 2001; 57: 89–91.
18. Giezen TJ, Mantel-Teeuwisse AK, Straus SMJM, et al. Safety-related regulatory actions for biological approved in the United States and the European Union. JAMA. 2008; 300: 1887–1896.
19. Mol PGM, Straus SMJM, Piening S, et al. A decade of safety-related regulatory action in the Netherlands. Drug Saf. 2010; 33: 463–474.